Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Lifted by Wellington Management Group LLP

Wellington Management Group LLP grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 46.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,813 shares of the company's stock after acquiring an additional 22,096 shares during the quarter. Wellington Management Group LLP owned about 0.10% of Kiniksa Pharmaceuticals worth $1,381,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KNSA. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth about $61,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth about $158,000. Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth about $160,000. Tower Research Capital LLC TRC increased its stake in Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after acquiring an additional 4,575 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after acquiring an additional 719 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KNSA shares. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Wedbush reiterated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Wall Street Zen lowered Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Citigroup started coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $38.80.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company's stock, valued at approximately $510,815.50. This represents a 61.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Ross Moat sold 27,594 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the completion of the transaction, the insider now directly owns 9,415 shares of the company's stock, valued at $273,223.30. This represents a 74.56% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 391,014 shares of company stock valued at $10,101,143. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.71 during trading hours on Friday, reaching $30.23. The company had a trading volume of 1,070,343 shares, compared to its average volume of 503,899. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.27. The company has a market capitalization of $2.21 billion, a P/E ratio of -215.91 and a beta of 0.06. The stock's fifty day simple moving average is $24.27 and its 200 day simple moving average is $21.90.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.25) earnings per share. As a group, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.